Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.
Carmelo GurnariSimona PagliucaPedro Henrique PrataJacques-Emmanuel GalimardLuis Fernando B CattoLise LarcherMarie SebertVincent AllainBhumika J PatelArda DurmazAndré Luiz PintoMariana C B InacioLucie HernandezNathalie DhedinSophie Caillat-ZucmanEmmanuelle ClappierFlore Sicre de FontbruneMaria Teresa Teresa VosoValeria VisconteRégis Peffault de LatourJean SoulierRodrigo T CaladoGerard SocièJaroslaw P MaciejewskiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The risk of sMN in AA is associated with disease severity, lack of response to treatment, and patients' age. sMNs display high-risk morphological, karyotypic, and molecular features. The landscape of acquired somatic mutations is complex and incompletely understood and should be considered with caution in medical management.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- healthcare
- blood pressure
- atrial fibrillation
- peritoneal dialysis
- prognostic factors
- gene expression
- single molecule
- dna methylation
- depressive symptoms
- copy number
- allogeneic hematopoietic stem cell transplantation
- combination therapy
- smoking cessation